Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-07-17
2007-07-17
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C435S235100, C424S204100
Reexamination Certificate
active
11170056
ABSTRACT:
A VP2 protein isolated from a variant Georgia strain of Infectious Bursal Disease Virus (IBDV) and method of generating such VP2 protein and variant strain for use to reduce or prevent infection in poultry by IBDV.
REFERENCES:
patent: 5064646 (1991-11-01), Snyder
patent: 5472858 (1995-12-01), Attie et al.
patent: 5518724 (1996-05-01), Snyder, et al.
patent: 5595912 (1997-01-01), Vakharia et al.
patent: 5632989 (1997-05-01), Snyder et al.
patent: 5788970 (1998-08-01), Vakharia et al.
patent: 5871744 (1999-02-01), Vakharia et al.
patent: 6017759 (2000-01-01), Vakharia et al.
patent: 6087165 (2000-07-01), Raina et al.
patent: 6156314 (2000-12-01), Vakharia et al.
patent: 6231868 (2001-05-01), Vakharia et al.
patent: 6274147 (2001-08-01), Vakharia et al.
patent: 6596280 (2003-07-01), Vakharia et al.
patent: 6936256 (2005-08-01), Vakharia
patent: 2003/0072772 (2003-04-01), Vakharia
patent: WO 9116925 (1991-11-01), None
Caston et al., “C Terminus of Infectious Bursal Diseas Virus Major Capsid Protein VP2 Is Involved in Definition of the T Number for Capsid Assembly,” Journal of Virology, Nov. 2001, vol. 75, No. 22, pp. 10815-10828.
Kato et al., “Identification and characterization of Marek's disease virus serotype 1 (MDV1) ICP22 gene product: MDV1 ICP22 transactivates the MDV1 ICP27 promoter syneergistically with MDV1 ICP4,” Veterinary Microbiology vol. 85, p. 305-313 (2002).
Macreadie et al., “Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast,” Vaccine, vol. 8 Dec. 1990 (p. 549-552).
Wang et al., “Identification of Neutralizatng Epitopes on the VP2 Protein of Infectious Bursal Disease Virus by Phage-Displayed Heptapeptide Library Screening and Synthetic Peptide Mapping,” Viral Immunology, vol. 18, No. 3, 2005.
Result 1 from us-11-170-056-5.rag.
Result 2 from us-11-170-056-6.rng.
Result 5 from us-11-170-056-6.rge.
Hunt, “From gene to protein: a review of new and enabling technologies for multi-parallel protein expression,” Protein Expression and Purification, 40 (2005) 1-22.
Muller et al., “Research on infectious bursal disease—the past, the present and the future,” Veterinary Microbiology 97 (2003) 153-165.
Rodriguez-Chavez et al., “Characterization of the antigenic, immunogenic, and pathogenic variation of infectious bursal disease virus due to propogation in different host systems (bursa, embryo and cell culture). I. Antigenicity and Immunogenicity,” Avian Pathology 2002, 31, 463-71.
Muller et al., “Research on infectious bursal disease-the past, the present and the future,” Veterinary Microbiology, 97, pp. 153-165 (2003).
Azad, A.A., Jagadish, M.N., Brown, M.A., et al., 1987, Deletion mapping and expression inEscherichia coliof the large genomic segment of a birnavirus,Virology161 (1): 145-152.
Brandt, M., Yao, K., Liu, M., Heckert, R.A. and Vakharia, V.N., 2001, Molecular determinants of virulence, cell tropism, and pathogenic phenotype of infectious bursal disease virus,J. Virol. 75, pp. 11974-11982.
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., Prasher, D. C. 1994. Green fluorescent protein as a marker for gene expression.Science263: 802-805.
Crameri, A., Whitehorn, E. A., Tate, E., Stemmer, W. P. C., 1996, Improved green fluorescent protein by molecular evolution using DNA shuffling.Nature Biotechnol. 14: 315-319.
Dobos, P., Hill, B.J., Hallett, R., Kells, D.T., Becht, H., and Teninges, D., 1979 Biophysical and biochemical characterization of five animal viruses with bisegmented double-stranded RNA genomes,J. Virol. 32, pp. 593-605.
Fernandez-Arias, A., Risco, C., Martinez, S., Albar, J.P., Rodriguez, J.F. 1998 Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles.J. Gen Virol. 79:1047-54.
Frank, M.B., 1998 Insect Cell Culture & Baculovirus Infections.In: Molecular Biology Protocols. (http://omrf.ouhsc.edu/˜frank/baculpro.html).
Hu, Y.C., Bentley, W.E., Edwards, G.H., Vakharia, V.N. 1999 Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography.Biotechnol Bioeng. 63:721-729.
Hudson, P.J., McKern, N.M., Power, B.E. and Azad, .A.A., 1986 Genomic structure of the large RNA segment of infectious bursal disease virus,Nucleic Acids Res. 14, pp. 5001-5012.
Kibenge, F. S. B., Dhillon, A.S., Russell, R.G., 1988, Biochemistry and immunology of infectious bursal disease virus,Journal of General Virology69: 1757-1775.
Kibenge, F.S., Qian, B., Nagy E., Cleghorn, J.R., Wadowska, D. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells.Can J. Vet Res. 1999, 63(1):49-55 (abstract).
Lombardo, E., Maraver, A., Caston, J.R., Rivera, J., Fernandez-Arias, A., Serrano, A., Carrascosa, J.L., Rodriguez, J.F. VP1, the putative RNA-dependant RNA polymerase of infectious bursal disease virus, forms complexes with the capsid protein VP3, leading to efficient encapsidation into virus-like particles.J. Virol. 1999, 73(8) 6973-83.
Maeda, S., Kawai, T., Obinata, M., Fujiwara, H., Horiuchi, T., Saeki, Y., Sato, Y., Furusawa, M. 1985. Production of human .alpha.-interferon in silkworm using a baculovirus vector.Nature315: 592-594.
Martinez-Torrecuadrada, J.L., Caston, J.R., Castro, M., Carrascosa, J.L., Rodriguez, J.F., Casal, J.I. 2000 Different architectures in the assembly of infectious bursal disease virus capsid proteins expressed in insect cells.Virology. 278:322-331.
Marumoto, Y., Sato, Y., Fujiwara, H., Sakano, K., Sakei, Y., Agata, M., Furusawa, M., Maeda, S. 1987. Hyperproduction of polyhedrin-IGF II fusion protein in silkwormlarvaeinfected with recombinantBombyx morinuclear polyhedrus virus.J. Gen. Virol. 68: 2599-2606.
Medin, J. A., Hung, L., Gathy, K., Evans, R. K., Coleman, M. S. 1990. Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insectlarvae. Proc. Nat. Acad. Sci. USA87: 2760-2764.
Miyajima, A., Schreurs, J., Otsu, K., Kondo, A., Arai, K., Maeda, S., 1987, Use of silkworm,Bombyx mori, and an insect baculovirus vector for high-level expression and secretion of biologically active mouse interleukin-3,Gene58: 273-281.
Muller, H. and Becht, H. 1982, Biosynthesis of virus-specific proteins in cells infected with infectious bursal disease virus and their significance as structural elements for infectious virus and incomplete particles,Journal of Virology44 (1): 384-392.
Mundt, E., and V. N. Vakharia, V.N., 1996, Synthetic transcripts of double-stranded birnavirus genome are infectious.Proc. Natl. Acad. Sci. USA93:11131-11136.
Prasher, D. C., Echenrode, V. K., Ward, W. W., Prendergast, F. G., Cormier, M. J, 1992, Primary structure of theAequorea victoriagreen-fluorescent protein,Gene, 111:229-233.
Robertson, B.H., Morgan, D.O., Moore, D.M. 1984, Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, vp1, of foot-and-mouth-disease virus-a12,Virus Research1 (6): 489-500.
Sanger, F., Nicklen, S.and Coulson, A.R., 1977, DNA sequencing with chain-terminating inhibitors,Proc. Natl. Acad. Sci. U.S.A. 74: pp. 5463-5467.
Shimomura, O., Johnson, F. H., Saiga, Y. 1962. Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan. Aequorea.J. Cell. Comp. Physiol. 59: 223-227.
Snyder, D.B., Vakharia, V.N., Savage, P.K., 1992, Naturally occurring-neutralizing monoclonal-antibody escape variants define the epidemiology of infectious bursal disease viruses in the United States,Arch. Virol. 127: 89-101.
Snyder, D.B., Vakharia, V.N., Mengel-Whereat, S.A., et al., 1994, Active cross-protection induced by a recombinant baculovirus expressing chimeric infectious bursal disease virus structural proteins,Avian Diseases38 (4): 701-707.
Vakharia, V.N. 1997, Biotechnology Annual Review vol. 3, 151-168.
Vakharia, V.N., Snyder, D.B., He, J., Edwards, G.H., Savage, P.K., and Mengel-
Campell Bruce R.
Hultquist Steven J.
Intellectual Property / Technology Law
Reynolds Kelly K.
Salvoza M. Franco
LandOfFree
Infectious bursal disease virus (IBDV) variant from Georgia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Infectious bursal disease virus (IBDV) variant from Georgia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Infectious bursal disease virus (IBDV) variant from Georgia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763317